Darunavir is predominantly unbound to protein in cerebrospinal fluid and concentrations exceed the wild-type HIV-1 median 90% inhibitory concentration
about
ING116070: a study of the pharmacokinetics and antiviral activity of dolutegravir in cerebrospinal fluid in HIV-1-infected, antiretroviral therapy-naive subjects.Virologic response, early HIV-1 decay, and maraviroc pharmacokinetics with the nucleos(t)ide-free regimen of maraviroc plus darunavir/ritonavir in a pilot study.HIV-associated neurocognitive disorders: perspective on management strategiesEffect of protein binding on unbound atazanavir and darunavir cerebrospinal fluid concentrations.HIV-1, HCV and alcohol in the CNS: potential interactions and effects on neuroinflammation.Pharmacokinetics of Once Versus Twice Daily Darunavir in Pregnant HIV-Infected Women.Etravirine in CSF is highly protein boundDarunavir: a review of its use in the management of HIV-1 infection.Pharmacokinetics and pharmacodynamics of boosted once-daily darunavir.Pharmacokinetics and pharmacodynamics of antiretrovirals in the central nervous system.Cerebrospinal Fluid HIV Escape from Antiretroviral Therapy.Darunavir/cobicistat for the treatment of HIV-1: a new era for compact drugs with high genetic barrier to resistance.Nanoformulated Antiretrovirals for Penetration of the Central Nervous System: State of the Art.Central nervous system penetration of antiretroviral drugs: pharmacokinetic, pharmacodynamic and pharmacogenomic considerations.Antiviral activity and CSF concentrations of 600/100 mg of darunavir/ritonavir once daily in HIV-1 patients with plasma viral suppression.Reduced antiretroviral drug efficacy and concentration in HIV-infected microglia contributes to viral persistence in brain.
P2860
Q34202181-DE321EAF-1141-4EB6-B7C6-C713EF0BA7C6Q34400849-18847E73-3FBE-4579-A2B2-14228A3F2E0EQ34652590-F4860947-B073-4056-8825-61F2073AD168Q35404442-73A8BFEA-39A0-43A3-8B20-9285AC8946BBQ35596364-08F398E1-F439-49DA-A6B1-59CE6AE97959Q36084313-38DE55C3-C536-4129-BD30-AD496EB48C26Q36762988-8BAA1AC9-B355-4FD6-9911-1E558156F62BQ38171346-3F2F18C6-8248-44DA-85EA-C7AB12C7FCA9Q38222092-81C1C785-F96C-4C92-8B51-5D8707219C59Q38247035-1862304F-E071-443A-826E-A53DF971E25AQ38414364-0435D86C-DFD1-4C9B-881B-F6A46777A65DQ38650067-8E72A579-374C-48EA-9E00-505CD82E656CQ39004638-5C6442FA-89D2-4325-A43F-9B6812360D3DQ41208022-0056BB3E-8F30-4F81-9E32-0D3613A704D8Q41530032-52E9A389-0D80-449D-8A52-4CCD5ED539B6Q42689787-BB296660-04C9-4496-9B5B-580288D04507
P2860
Darunavir is predominantly unbound to protein in cerebrospinal fluid and concentrations exceed the wild-type HIV-1 median 90% inhibitory concentration
description
2012 nî lūn-bûn
@nan
2012年の論文
@ja
2012年論文
@yue
2012年論文
@zh-hant
2012年論文
@zh-hk
2012年論文
@zh-mo
2012年論文
@zh-tw
2012年论文
@wuu
2012年论文
@zh
2012年论文
@zh-cn
name
Darunavir is predominantly unb ...... n 90% inhibitory concentration
@ast
Darunavir is predominantly unb ...... n 90% inhibitory concentration
@en
type
label
Darunavir is predominantly unb ...... n 90% inhibitory concentration
@ast
Darunavir is predominantly unb ...... n 90% inhibitory concentration
@en
prefLabel
Darunavir is predominantly unb ...... n 90% inhibitory concentration
@ast
Darunavir is predominantly unb ...... n 90% inhibitory concentration
@en
P2093
P2860
P50
P356
P1476
Darunavir is predominantly unb ...... n 90% inhibitory concentration
@en
P2093
Ann C Collier
Benjamin B Gelman
Brookie M Best
Christina M Marra
David B Clifford
David Croteau
David M Simpson
Edmund Capparelli
J Allen McCutchan
Justin McArthur
P2860
P304
P356
10.1093/JAC/DKS441
P407
P577
2012-11-09T00:00:00Z